Antibiotic Trial Continues Despite Reported Threat to Children
Submitted by Jonathan Rosenblum on
A new antibiotic that has been found to cause four times the average rate of acute liver failure in adults continues in a trial for more than 900 children worldwide, despite criticism from a U.S. Food and Drug Administration official and a study consultant. The drug, Ketek (internationally known as Telithromycin) is manufactured by Sanofi-Aventis, a French pharmaceutical firm with U.S.